BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 2675659)

  • 1. Hematopoietic hormones: from cloning to clinic.
    Perrine SP; Vichinsky E; Faller DV
    Am J Pediatr Hematol Oncol; 1989; 11(3):268-75. PubMed ID: 2675659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Special Education.
    Kozutsumi H
    Oncologist; 1996; 1(1 & 2):116-118. PubMed ID: 10387976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of colony-stimulating factor(s) for granulocyte-macrophage and multipotential (granulocyte/erythroid/megakaryocyte/macrophage) hematopoietic progenitor cells (CFU-GEMM) by clonal lines of human IL-2-dependent T-lymphocytes.
    Greenberger JS; Krensky AM; Messner H; Burakoff SJ; Wandl U; Sakakeeny MA
    Exp Hematol; 1984 Oct; 12(9):720-7. PubMed ID: 6333354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical application of hematopoietic growth factor (IL-3, G-CSF, GM-CSF, and EPO)].
    Motoyoshi K
    Nihon Rinsho; 1992 Aug; 50(8):1967-72. PubMed ID: 1279240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-7 stimulates CSF-induced proliferation of murine bone marrow macrophages and Mac-1+ myeloid progenitors in vitro.
    Jacobsen FW; Veiby OP; Jacobsen SE
    J Immunol; 1994 Jul; 153(1):270-6. PubMed ID: 8207241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future strategies in the control of myelosuppression: the use of colony-stimulating factors.
    Haeuber D
    Oncol Nurs Forum; 1991 Mar; 18(2 Suppl):16-21. PubMed ID: 2047296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The colony-stimulating factors: biology and clinical use.
    Glaspy JA; Golde DW
    Oncology (Williston Park); 1990 Sep; 4(9):25-32; discussion 32-4. PubMed ID: 2145019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Special Education: Aplastic Anemia.
    Teramura M; Mizoguchi H
    Oncologist; 1996; 1(3):187-189. PubMed ID: 10387986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physician Education: The Erythropoietin Receptor and Signal Transduction.
    Yoshimura A; Arai K
    Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-11 stimulates the proliferation of human hematopoietic CD34+ and CD34+CD33-DR- cells and synergizes with stem cell factor, interleukin-3, and granulocyte-macrophage colony-stimulating factor.
    Lemoli RM; Fogli M; Fortuna A; Motta MR; Rizzi S; Benini C; Tura S
    Exp Hematol; 1993 Dec; 21(13):1668-72. PubMed ID: 7694867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic growth factors and glucocorticoids synergize to mimic the effects of IL-1 on granulocyte differentiation and IL-1 receptor induction on bone marrow cells in vivo.
    Dubois CM; Neta R; Keller JR; Jacobsen SE; Oppenheim JJ; Ruscetti F
    Exp Hematol; 1993 Feb; 21(2):303-10. PubMed ID: 7678814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinations of colony-stimulating factors promote enhanced proliferative potential in enriched granulocyte-macrophage colony-forming cells.
    Heyworth CM; Dexter TM; Nicholls SE; Whetton AD
    Exp Hematol; 1994 Oct; 22(11):1089-94. PubMed ID: 7925776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cytokines in the treatment of blood diseases].
    Robak T
    Acta Haematol Pol; 1995; 26(2 Suppl 1):72-8. PubMed ID: 7544526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current status of the clinical application of hematopoietic growth factors in oncology].
    Karthaus M; Ganser A
    Ther Umsch; 1996 Nov; 53(11):863-73. PubMed ID: 8984692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients.
    Schneider JG; Crown JP; Wasserheit C; Kritz A; Wong G; Reich L; Norton L; Moore MA
    Bone Marrow Transplant; 1994 Dec; 14(6):877-84. PubMed ID: 7536069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine-dependent ex vivo expansion of early subsets of CD34+ cord blood myeloid progenitors is enhanced by cord blood plasma, but expansion of the more mature subsets of progenitors is favored.
    Ruggieri L; Heimfeld S; Broxmeyer HE
    Blood Cells; 1994; 20(2-3):436-54. PubMed ID: 7538350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical use of hematopoietic growth factors.
    Appelbaum FR
    Semin Hematol; 1989 Jul; 26(3 Suppl 3):7-14. PubMed ID: 2477905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effects of purified recombinant human and murine B cell growth factor-1/IL-4 on colony formation in vitro by hematopoietic progenitor cells. Multiple actions.
    Broxmeyer HE; Lu L; Cooper S; Tushinski R; Mochizuki D; Rubin BY; Gillis S; Williams DE
    J Immunol; 1988 Dec; 141(11):3852-62. PubMed ID: 3053902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.